Vycor Medical, Inc.
VYCO
Other OTC0.07
USD
- -
- -
Vycor Medical, Inc.
VYCO
(Other OTC)
Recent
price
0.07
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Vycor Medical, Inc. is a medical technology company specializing in the design, development, and marketing of innovative medical devices for neurosurgery and neurotherapeutic solutions. Its core products include the ViewSite Brain Access System (VBAS), a suite of FDA-cleared, clear cylindrical disposable devices used to access tumors and other targets within the brain during minimally invasive neurosurgical procedures. The VBAS is designed to optimize surgical site access, reduce patient risk, accelerate recovery, and improve neurological outcomes. Vycor Medical operates two main divisions: Vycor Medical, focused on the neurosurgical device portfolio, and NovaVision, which develops FDA-registered, non-invasive, computer-based light stimulation therapies for vision disorders caused by stroke or neurological brain injuries. NovaVision's offerings include the Vision Restoration Therapy (VRT) and NeuroEyeCoach (NEC) therapies, aimed at restoring and rehabilitating vision impairments resulting from neurological trauma. Recent major company developments include a strategic partnership with HelferApp for exclusive licensing rights of NovaVision's diagnostic products and therapies in Germany, Austria, and Switzerland, marking a shift to a license-based model for European operations. Vycor Medical also reported steady financial growth with a 31% year-over-year revenue increase in its neurosurgery division for Q3 2025, driven by both U.S. and international market expansion. The company has strengthened its clinical validation with multiple peer-reviewed studies supporting its VBAS technology, including promising results in intracerebral hemorrhage evacuation. NovaVision's vision therapy demonstrated effective outcomes for both home-based and clinic-based treatments, aligning with trends toward remote healthcare delivery. Vycor Medical targets healthcare providers and neurosurgical centers globally, with operations primarily in the United States, Germany, and the United Kingdom. Founded in 2001 and headquartered in Boca Raton, Florida, Vycor Medical has expanded its portfolio through acquisitions, notably acquiring NovaVision Inc. in 2020 to enhance its neurotherapeutic offering. The company maintains a robust scientific advisory team and continues to innovate in neurosurgical access devices and vision rehabilitation technologies, serving patients with complex brain and neurological conditions while advancing minimally invasive surgical techniques and therapeutic rehabilitation options. Vycor Medical's continued focus on evidence-based medical solutions and strategic partnerships positions it as a growing player in the medical device industry for neurosurgery and neurological rehabilitation markets. The leadership team includes CEO Peter Zachariou and President David Cantor, who drive the company's mission to deliver innovative solutions that improve patient outcomes and provide value to the medical community.